论文部分内容阅读
Ⅲ期原发性肝癌患者44例,行肝动脉单途径灌注化疗29例,行肝动脉、门静脉双途径灌注化疗15例.结果:两组肿瘤缓解率、AFP下降率相近,平均治后生存期无显著性差异.但双途径组治后半年以上生存率显著高于单途径组,且有两例门静脉癌栓缩小.
In 44 patients with stage III primary liver cancer, 29 patients underwent hepatic artery single-pass infusion chemotherapy and 15 patients underwent hepatic artery and portal vein dual-channel infusion chemotherapy. Results: The rate of tumor remission and AFP decreased similarly in the two groups, and the average post-treatment survival period There was no significant difference. However, the survival rate of the two-way group after treatment for more than half a year was significantly higher than that of the single-pathway group, and two cases of portal vein tumor thrombus were reduced.